Apogee eczema drugs gets Blackstone backing, heads to Phase 3

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, ...
Investor's Business Daily on MSN

Why Apogee slipped on its Dupixent-rivaling eczema results

Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.
Fierce Biotech

Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3

Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences (BXLS) as the ...

Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing

Apogee Therapeutics advances zumilokibart with a $1.3B Blackstone deal, eyes $82.97 value despite asset risks. Read why APGE ...

Apogee secures up to $1.3 billion from Blackstone to advance eczema drug

By Kunal Das May 27 (Reuters) - Apogee Therapeutics on Wednesday posted favorable results from a mid-stage trial of its experimental eczema drug and secured a financing deal worth up to $1.3 billion ...